Navigation Links
Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
Date:5/17/2012

last week of the 12-week, double-blind maintenance phase, as determined by an 11-point pain rating scale or numerical rating scale (NRS; 0='no pain,' 10='pain as bad as you can imagine'). Safety assessments were performed on the open-label and double-blind safety populations (all patients who received greater than or equal to 1 dose of open-label and double-blind treatment, respectively). Treatment-emergent adverse events (TEAEs), defined as any AEs (new or worse in intensity) that occurred after the first intake of study drug during the open-label or double-blind phase, were monitored throughout the study.

In the open-label titration period, 459 patients received one or more doses of tapentadol ER and were included in the open-label safety population. At the start of the 3-week, open-label phase, the majority of patients (87.1 percent) reported severe pain (6 or more on the 11-point NRS) with a mean pain intensity of 7.3. By the end of the open-label phase, the mean pain intensity was reduced to 3.6. Treatment-emergent adverse events (TEAEs) experienced by 10 percent or more of patients during the open-label phase were nausea (24.4 percent), dizziness (17), constipation (11.8) and somnolence (10.7).

A total of 358 patients completed the open-label titration period; 318 were randomized and received one or more dose of study medication (n=152 for placebo, 166 for tapentadol ER).

Following randomization, during the double-blind treatment phase to week 12, pain increased in the placebo group (as demonstrated by the mean change in pain intensity of 1.3), while in the tapentadol ER group, efficacy was maintained, as indicated by the mean change in pain intensity of 0.28. The least-squares mean difference between the tapentadol ER and placebo groups in the change in average pain intensity was -0.95 on the 11-point NRS favoring tapentadol ER (95 percent CI, -1.42 to -0.49; p<0.001, tapentadol ER vs. placebo)(4).

For more details about the s
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
2. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
3. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
4. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
6. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
7. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
10. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... N.Y. , May 27, 2015  VirtualScopics, ... of clinical trial imaging solutions, announced today, ahead ... Medicine (ISMRM) Annual Meeting in Toronto ... operational investments in Magnetic Resonance Elastography (MRE).  VirtualScopics, ... supporting pharmaceutical companies integrating MRE into their global, ...
(Date:5/27/2015)... LONDON and NEW YORK ... - http://www.abmrg.com/Indonesia-Respiratory-Devices-and-Respiratory-Diagnostics-Market-through-2020---Detailed-analysis-of-Hospital-and-Retail-market.html - Over 70% Indonesian ... Around 400,000 Indonesians die annually due to smoking-related conditions; ... Three-fourths of 6.5 million vehicles in Jakarta ... Indonesia is the fourth ...
(Date:5/27/2015)... N.J. , May 27, 2015  Cambrex Corporation (NYSE: ... , Executive Vice President and Chief Financial Officer, will present ... 2015 at 8:00 a.m. EDT in New York ... slide presentation can be accessed from the Cambrex website at ... Presentations", and a replay will be available for 90 days ...
Breaking Medicine Technology:VirtualScopics, Inc. Makes Investments In Magnetic Resonance Elastography (MRE) 2VirtualScopics, Inc. Makes Investments In Magnetic Resonance Elastography (MRE) 3VirtualScopics, Inc. Makes Investments In Magnetic Resonance Elastography (MRE) 4Indonesia Respiratory Devices Market is Expected to Grow at a CAGR of 9% - Boosting Growth for Respiratory Disposables 2Indonesia Respiratory Devices Market is Expected to Grow at a CAGR of 9% - Boosting Growth for Respiratory Disposables 3Indonesia Respiratory Devices Market is Expected to Grow at a CAGR of 9% - Boosting Growth for Respiratory Disposables 4
... Calif., Oct. 6 PRO-DEX, INC. (Nasdaq: PDEX ... as Chief Financial Officer, effective October 6, 2010.  Mr. Hurwitz ... "Hal comes to Pro-Dex with a broad financial background ... with Coopers & Lybrand LLP, now part of PricewaterhouseCoopers LLP, ...
... DiFUSION Technologies Inc., a medical device company focused ... CleanFUZE™ anti-microbial technology for orthopedic implants, announced today ... of posterior interbody devices indicated for intervertebral body ... SI, in skeletally mature patients who have had ...
Cached Medicine Technology:Pro-Dex, Inc. Appoints Harold A. Hurwitz as Chief Financial Officer 2DiFUSION Technologies Receives 510(k) Clearance of Xiphos™ Interbody Implants for Spinal Fusion 2
(Date:5/27/2015)... May 27, 2015 SAN DIEGO, ... Gulfport Mississippi, is the first healthcare provider along ... to chronic care management (CCM). In partnership with ... is introducing RevUp, a new program that enables ... and increase monthly reimbursements. This new, user-friendly program ...
(Date:5/27/2015)... May 27, 2015 Coco Libre announced today ... able to reach for Organic Coconut Water to quench their ... be available at VIP areas, artist greenrooms, corporate skyboxes and ... at area hotels and on festival shuttle buses. , ... year,” said Noa Elan, Director of Strategic Partnerships for Latitude ...
(Date:5/27/2015)... 27, 2015 This is a ... of the Omega-3 industry. The report provides a ... applications and industry chain structure. The Omega-3 market ... development trends, competitive landscape analysis, and key regions ... Camanchaca Fishing Company, Seadragon Marine Oils, Norwegian Fish ...
(Date:5/27/2015)... With InnerVoice Communication App you will ... is not only heard but seen -- by a photograph ... image. This award-winning and affordable app takes full advantage of ... InnerVoice Sender app in conjunction with InnerVoice Communication ... remotely for no additional cost. , InnerVoice Sender ...
(Date:5/27/2015)... For a limited time, San Fernando ... discounts on facial fillers. Skin loses more than 2 percent ... This lost collagen can lead to thinning or sagging skin, ... Facial fillers are an excellent way to plump skin and ... to create a softer and more youthful appearance, without the ...
Breaking Medicine News(10 mins):Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 2Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 3Health News:Newly Released: InnerVoice Sender App Ups the Ante in Communication Technology for Autism with Remote Prompting 4Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Discounts on Facial Fillers 2
... Announced the Initiation of the Phase III ... to Treat Rheumatoid Arthritis., COPENHAGEN, Denmark, November 20 ... GSK) announced today the,initiation of the Phase III program ... commence with two studies,(GEN410/OFA110635 and GEN411/OFA110634) which will be ...
... November 20 With the recent,FDA approval of ... and follow-up of cancerous or other potentially malignant,lesions ... Technologies,succeeds in setting the trend in diagnostic oncology ... Lesion Management Solutions at the,93rd annual meeting of ...
... Nov. 16 For patients with,rheumatoid arthritis, combining one ... medications often works best to reduce joint,swelling or tenderness, ... for,Healthcare Research and Quality, part of the U.S. Department ... report will be posted on-line,Monday in the Annals of ...
... 19 If you or someone you know,has been ... or medical,personnel working with lung cancer patients, you won,t ... Advocacy Conference. The conference,co-presented by the American Lung Association ... be held Friday, Nov. 30, at the,Ritz-Carlton Dearborn. Medical ...
... healthy individuals, have made a key discovery in understanding ... and remain untreated by the bodys own natural defences. ... 23 November) by the Proceedings of the National Academy ... , Under normal circumstances, the immune system creates ...
... studies suggest , , MONDAY, Nov. 19 (HealthDay News) -- People ... and dementia as they age, two new studies suggest. ... pressure increased the risk of developing disabilities, such as not ... or bathe oneself. , "High blood pressure affects many ...
Cached Medicine News:Health News:Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program 2Health News:Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program 3Health News:Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program 4Health News:MEDIAN Technologies Lesion Management Solutions Set the Trend in Diagnostic Oncology Imaging at RSNA 2007 2Health News:Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis 2Health News:Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis 3Health News:BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivor's Perspective 2Health News:BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivor's Perspective 3Health News:BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivor's Perspective 4Health News:BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivor's Perspective 5Health News:BREATHE Lung Cancer Conference, Nov. 30, Offers Medical and Patient Education, Advocacy and Survivor's Perspective 6Health News:New research helps explain how tumors go undetected by the body 2Health News:High Blood Pressure Linked to Disability, Dementia 2Health News:High Blood Pressure Linked to Disability, Dementia 3
... portable NEVA™ System is designed ... changes within the penis nocturnally. ... to monitor and record impedance ... changes in penile blood volume. ...
... designed for vascular labs already equipped ... Its primary use will be for ... cuff with air. Blood pressures ... - a proximal occluding cuff connected ...
... your patients come to you with ... they can understand. Then they want ... Rigidity Assessment System can you gather, ... rigidity and tumescence data...and provide the ...
... The table top design takes into ... and creates a flexible working environment for ... the alphamaxx can be matched exactly to ... top slide capability creates superior access for ...
Medicine Products: